Phaseline

Targets › LAMB3

LAMB3 (Laminin subunit beta-3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other.

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. (UniProt, Q13751)

Open in Phaseline: the race on LAMB3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Southern CaliforniaGentamicin
Bacterial 70S ribosome inhibitor
LAMB3, LAMA3, LAMC2Phase 1Junctional Epidermolysis Bullosa–

Conditions

Junctional Epidermolysis Bullosa (1)

Modalities

small molecule (1)

Companies

University of Southern California (1)

Related targets

LAMA3 (1) LAMC2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.